Healthcare Finance News May 22, 2024
The court left room for the possibility of future enforcement if 340B conditions are violated.
An appeals court has upheld a lower court ruling on 340B that sided with drug manufacturers.
At issue is whether pharmaceutical companies can limit distribution of discounted drugs in the 340B program. The U.S. Court of Appeals for the District of Columbia has said that they can.
The May 21 ruling issued by Circuit Court Judge Gregory Katsas favors Novartis Pharmaceuticals Corporation and United Therapeutics Corporation over the Department of Health and Human Services and the Health Resources and Service Administration.
WHY THIS MATTERS
Providers benefit from 340B through insurance reimbursements that exceed the marked-down cost of the drugs.
The ceiling price is fixed by...
Today's Sponsors
Today's Sponsor